Loveland, OH, United States of America

Adam Golebiowski


Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 2001-2009

Loading Chart...
9 patents (USPTO):Explore Patents

Title: Adam Golebiowski: Innovator in Cytokine Inhibition

Introduction

Adam Golebiowski is a prominent inventor based in Loveland, OH (US). He has made significant contributions to the field of cytokine inhibition, holding a total of 9 patents. His work focuses on developing innovative solutions to combat inflammatory diseases.

Latest Patents

Among his latest patents, Golebiowski has developed "Bicyclic pyrazolone cytokine inhibitors." This invention relates to 6,7-dihydro-5H-pyrazolo[1,2α]pyrazol-1-ones, which inhibit the extracellular release of inflammatory cytokines responsible for various human or higher mammalian disease states. The invention also includes compositions comprising these compounds and methods for controlling the enzymes that are active components in these disease states.

Another notable patent is for "Tri-substituted ureas as cytokine inhibitors." This invention involves 1,1,3-tri-substituted ureas that similarly inhibit the extracellular release of inflammatory cytokines. It also encompasses compositions containing these ureas and methods for managing the enzymes linked to the described disease states.

Career Highlights

Adam Golebiowski is currently associated with The Procter & Gamble Company, where he continues to innovate in the field of cytokine inhibition. His work has the potential to significantly impact the treatment of inflammatory diseases.

Collaborations

Golebiowski has collaborated with notable colleagues, including Michael Philip Clark and Todd Andrew Brugel. Their combined expertise contributes to the advancement of research in cytokine inhibitors.

Conclusion

Adam Golebiowski is a dedicated inventor whose work in cytokine inhibition is paving the way for new therapeutic approaches. His contributions are vital in addressing inflammatory diseases and improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…